Overexpression and Selective Anticancer Efficacy of ENO3 in STK11 Mutant Lung Cancers

Oncogenic gain-of-function mutations are clinical biomarkers for most targeted therapies, as well as represent direct targets for drug treatment. Although loss-of-function mutations involving the tumor suppressor gene, STK11 (LKB1) are important in lung cancer progression, STK11 is not the direct ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Choa, Lee, Yejin, Je, Soyeon, Chang, Shengzhi, Kim, Nayoung, Jeong, Euna, Yoon, Sukjoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Molecular and Cellular Biology 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883975/
https://www.ncbi.nlm.nih.gov/pubmed/31697874
http://dx.doi.org/10.14348/molcells.2019.0099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883975/
https://www.ncbi.nlm.nih.gov/pubmed/31697874
http://dx.doi.org/10.14348/molcells.2019.0099

Ejemplares similares